Related by context. All words. (Click for frequent words.) 78 Metabolic Drugs Advisory 78 FDA Oncologic Drugs 78 Arthritis Advisory 77 Psychopharmacologic Drugs Advisory 77 Antiviral Drugs Advisory 76 Ophthalmic Drugs Advisory 74 FDA Endocrinologic 74 Drugs Advisory 74 FDA Pulmonary Allergy 72 Anti Infective Drugs 72 FDA Dermatologic 71 FDA Anti Infective 71 Pulmonary Allergy Drugs 70 FDA Advisory Panel 69 Nonprescription Drugs Advisory 69 Renal Drugs Advisory 68 Gastrointestinal Drugs Advisory 68 Endocrinologic 68 FDA Psychopharmacologic Drugs 67 FDA Antiviral Drugs 65 AIDAC 65 Human Medicinal Products 64 FDA Oncologic Drug 64 Proprietary Medicinal Products CPMP 63 Oncologic Drug Advisory 63 Proprietary Medicinal Products 62 Metabolic Drugs 62 Drug Administration FDA Oncologic 62 Recombinant DNA Advisory 62 Drug Administration Oncologic Drugs 61 FDA Nonprescription Drugs 61 Ocrelizumab 60 approvability 60 FDA approvable letter 60 CHMP 60 Society CTOS 60 Complete Response 60 CHMP recommendation 60 European Medicines Evaluation 60 FDA Approvable Letter 59 Gene Therapy Advisory 59 Orphan Medicinal Products 59 Biologic License Application BLA 59 Drug Administration FDA Endocrinologic 59 Enhance ITEX 59 MEDCAC 59 ASCO GI 59 Hedgehog Pathway Inhibitor 59 NASDAQ Listing Qualification 58 PDUFA Date 58 Immunisation Practices 58 Product Monograph 58 SUCCEED trial 58 Enhance Topps 58 Telavancin 58 Gilenia 58 Nasdaq CYCC Nasdaq CYCCP 58 ezogabine 58 BCIRG 58 Roche Actemra 58 AVERROES 58 Medicinal Products EMEA 58 guanfacine extended release 58 Xinlay 57 Romiplostim 57 Vion Pharmaceuticals 57 Board DSMB 57 PRNewswire FirstCall Genta Incorporated 57 Nabi HB Intravenous 57 ICAAC IDSA 57 Febuxostat 57 Not Approvable 57 BLA filing 57 MAA submission 57 Esbriet ® 57 Tanespimycin 57 Plicera 57 Late Breaker 57 Final Appraisal Determination 57 APPRAISE 57 ANTEGREN 57 Nexavar sorafenib 56 Orathecin 56 Auxilium Pharma 56 DSMB 56 ALLSCHWIL BASEL SWITZERLAND 56 Raptiva R 56 Resubmission 56 Biological Therapy 56 Medicinal Products 56 Electoral Boundaries Review 56 rALLy trial 56 RSR# 56 Clinical Trials Update 56 Velcade bortezomib 56 Fablyn 56 CLARITY study 56 sNDA submission 56 Connective Tissue Oncology 56 Onrigin 56 Nasdaq OSCI 56 Zarnestra 56 Nasdaq ONXX today 56 LibiGel ® 56 Tarceva TM 56 brivaracetam 56 FDA Complete Response 56 Canaccord Adams Hepatitis C 56 NASDAQ TARG 56 alvimopan 56 SmPC 56 NASDAQ CXSP announced 55 Ranolazine 55 Vertex hepatitis C 55 Nasdaq ENZN 55 Nasdaq GNTA 55 MERLIN TIMI 55 Devices Advisory Panel 55 Celgene Revlimid 55 Complete Response Letter CRL 55 IL# PE#QQR 55 midstage clinical 55 oxymorphone ER 55 Immunization Practices ACIP 55 TPSAC 55 Nonprescription Drugs 55 STELARA TM 55 PDUFA date 55 figitumumab 55 Regeneron Pharma 55 Avastin bevacizumab 55 Egrifta 55 Accelerated Approval 55 vandetanib 55 PROVENGE ® 55 Dendreon Provenge 55 Nasdaq ADLR 55 arzoxifene 55 peginesatide 55 Junovan 55 Pirfenidone 55 Radiological Devices 55 CombAT 55 PROSTVAC TM 55 Intermezzo ® NDA 55 Complete Response letter 55 CONBRIZA 55 Whole COW 55 PRAECIS PHARMACEUTICALS INCORPORATED 55 Vectibix panitumumab 55 CHMP opinion 55 PRNewswire FirstCall Tercica 55 Human Use CHMP 55 ECTRIMS 55 Pre IND 55 Actelion Ltd 55 Sprycel dasatinib 55 iSBTc 55 PIX# [002] 55 AACR NCI EORTC 55 Inc. Nasdaq MLNM 55 Potiga 55 SIX ATLN 55 Clinical Oncology Annual Meeting 55 Dr. Gulfo 55 approvable letters 55 TORISEL TM 55 SABCS 55 PROVENGE sipuleucel T 55 Nuvion 54 Clolar 54 Inc. NASDAQ ACUS 54 Nasdaq OPTR 54 Arranon 54 ® darbepoetin alfa 54 ASCO GU 54 Abiraterone Acetate 54 Neurological Devices 54 Vectibix 54 Luveris 54 Interagency Autism Coordinating 54 Pivotal Phase III 54 Femara letrozole 54 Marketing Authorisation Application 54 PROMACTA 54 Inc. NASDAQ HEPH 54 EFNS 54 AACR San Antonio 54 Aflibercept 54 Troxatyl 54 desvenlafaxine succinate 54 Outcomes Research ISPOR 54 FDA reviewers 54 Risperidone Oral Solution 54 Brentuximab Vedotin SGN 54 OMP designation 54 Arzerra ofatumumab 54 PDUFA Prescription Drug 54 NASDAQ ISTA 54 National Coverage Determination 54 QNEXA 54 Kiacta 54 cetuximab Erbitux 54 NASDAQ PCYC 54 Sutent sunitinib malate 54 Temsirolimus 54 GAP Audit 54 Biological Effects 54 Prestara 54 Biologics Licensing 54 CUSTOM III 54 TEMODAL 54 Liver Disease AASLD 54 Clinical Oncologists 54 ARCOXIA 54 tramiprosate ALZHEMED TM 54 Orexigen Contrave 54 Pegloticase 54 bazedoxifene 54 Genetic Engineering Appraisal 54 Nebido 54 Nasdaq DVAX 54 Pivotal Clinical Trial 54 Lorqess 54 Targanta Therapeutics Corporation 53 Keryx Biopharma 53 AVASTIN 53 Certican 53 sorafenib Nexavar 53 Phase III ALLEGRO 53 IRESSA 53 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 53 SPARLON 53 CTI Nasdaq 53 vismodegib 53 ORAL Sync 53 Permanent Representatives COREPER 53 Menerba 53 Zalbin 53 Biologic License Application 53 ZOLINZA 53 myelodysplastic myeloproliferative diseases 53 Entereg 53 abstracts summarizing 53 Bifeprunox 53 ORENCIA ® 53 AMEX Listing Qualifications 53 Hedgehog antagonist 53 Radiation Oncology ASTRO 53 Complete Response Letter 53 Hsp# Inhibitor 53 Marketing Authorisation Application MAA 53 SWX BSLN 53 BLP# Liposome Vaccine 53 Tesmilifene 53 Amrubicin 53 Arpida 53 gadobutrol 53 Inc. Nasdaq TRCA 53 Dr. McHutchison 53 Serdolect ® 53 NASDAQ Hearings Panel 53 Coadministration 53 Telcyta 53 Amgen Vectibix 53 aflibercept 53 Breaking Clinical Trials 53 Amgen Nplate 53 BRIM2 53 testosterone gel LibiGel 53 ISO Vorin TM 53 Nasdaq MAXM SSE MAXM 53 TACI Ig 53 ENDEAVOR III 53 vinflunine 53 NEBIDO 53 pregabalin Lyrica 53 Afinitor everolimus 53 European Medicines Agency 53 AstraZeneca Iressa 53 Promacta 53 Velac 53 muraglitazar 53 Proellex 53 Endocrine Society ENDO 53 prucalopride 53 OPAXIO 53 Uvidem 53 abatacept 53 recurrent glioblastoma multiforme 53 sitaxsentan sodium 53 Genta Incorporated OTCBB GETA 53 selective modulator 53 Sparlon 53 FASB Emerging 53 Drug Eluting Stent System 53 CALGB # [002] 53 Alimta pemetrexed 53 supplemental Biologics License Application 53 Biogen Elan 53 abatacept Orencia 53 Canvaxin 53 Provenge prostate cancer 53 LymphoStat B 53 Nasdaq IMGN 53 FDA 53 Kynapid 53 Secretaries CoS 53 NYSE BVF TSX 53 Qnexa 53 ASCEND HF 53 Inc. NASDAQ BPAX 53 Ixempra 53 sitaxsentan 53 Cladribine 53 SPRYCEL ® 53 Increlex TM 53 Inc. NASDAQ AGIX 53 investigational antiplatelet agent 53 SCHWARZ PHARMA 53 Bonefos 53 Marketing Authorisation 53 lasofoxifene 53 Dacogen injection 53 Rebif ® 53 NIH Consensus 53 Tasigna nilotinib 52 Sanctura XR 52 FDA Circulatory System 52 comparing alemtuzumab 52 phase IIb study 52 Dietary Guidelines Advisory 52 autologous cellular immunotherapy 52 Angiox ® 52 Unanimously Recommends 52 virus HCV protease inhibitor 52 NASDAQ SHPGY 52 BOE Monetary Policy 52 ASGCT 52 DASISION study 52 Special Stockholder Meeting 52 Reactor Safeguards ACRS 52 Viviant 52 Panzem R 52 lucinactant 52 AASLD 52 NASDAQ BDSI 52 CICA Emerging 52 AVANDIA 52 Linjeta 52 Peginterferon alfa 2b 52 Talabostat 52 ACCLAIM II 52 Firazyr 52 PTK ZK 52 Glufosfamide 52 Nasdaq NABI 52 WTC Redevelopment 52 Pegintron 52 Ambrisentan 52 Myfortic 52 Recommends Approval 52 XGEVA ™ 52 Elan Tysabri 52 Endocrine Practice 52 Reverset 52 dalbavancin 52 Phase IIb trials 52 orphan medicinal product 52 Dose Escalation 52 TASKi2 52 AVADO 52 Gastrointestinal Drugs 52 NAEPP 52 DORIBAX 52 Androxal ® 52 Torisel temsirolimus 52 Act PDUFA date 52 Tezampanel 52 Marketing Authorization Application 52 RhuDex 52 Pivotal Trial 52 IMiDs ® compound 52 GATTEX TM 52 Fast Track Status 52 CTRC AACR San Antonio 52 #nd EORTC NCI 52 Hematology Meeting 52 pirfenidone 52 Eribulin 52 PROSTVAC ® 52 Immunization NACI 52 BioMarin Pharma 52 Bazedoxifene 52 ACTEMRA TM 52 Phase IIB 52 BRIM3 52 Reactor Safeguards 52 SNT-MC#/idebenone 52 Sanofi aventis EURONEXT SAN 52 Pediatric Academic Societies PAS 52 KRN# 52 ocrelizumab 52 AASLD Meeting 52 Roche MabThera 52 indiplon capsules 52 Adentri 52 number NCT# ClinicalTrials.gov 52 efalizumab 52 Hematological Malignancies 52 R rosiglitazone maleate 52 Vernakalant 52 Removab 52 ruboxistaurin 52 Ereska 52 BioDelivery Sciences 52 League Against Rheumatism 52 Belimumab 52 HoFH 52 ACCORD Lipid 52 Vicriviroc 52 Annuity Insurers 52 LSE ASM 52 balsalazide tablet 52 Application BLA 52 Combination REOLYSIN R 52 Aryplase 52 REVLIMID R 52 NASDAQ FLML 52 ixabepilone 52 TYZEKA 52 elotuzumab 52 ELACYT 52 Dasatinib 52 Vandetanib 52 ImClone Erbitux 52 Clinical Trial Results 52 Ramelteon 52 ONGLYZA ™ 52 Dermatologic 52 zanolimumab 52 Boceprevir 52 MyVax 52 Tracleer r 52 pertuzumab 52 FDA Accepts 52 midstage study 52 Photocure ASA 52 EASL 52 Muraglitazar 52 SUTENT ® 52 Krystexxa 52 CERVARIX R 52 Onyx Pharma 52 TYKERB 52 GTC recombinant form 52 ZEGERID Chewable Tablets 52 Glatiramer Acetate 52 Clinical Trial Data 52 denosumab 52 NASDAQ Listing 52 Nasdaq INCY announced 52 Gynecologic Oncology Group 51 TSX SHQ 51 Application MAA 51 ToGA 51 NYSE Amex PTN 51 ongoing Phase 1b 51 Celebrex celecoxib 51 Poster Discussion 51 highly purified pasteurized 51 mitogen activated ERK kinase 51 Amyvid 51 ATACAND 51 Combating Counterfeit Drugs 51 Investigational Compound 51 Elocalcitol 51 severe hypercholesterolemia 51 OTCQX RHHBY 51 NASDAQ AVNR 51 liver resection surgeries 51 Novartis Femara 51 Denufosol 51 Phase III TRIST 51 Cancers Symposium 51 Inc. Nasdaq RDYN 51 Phase III Clinical Trial 51 rasagiline tablets 51 Nasdaq ALXN 51 iloperidone 51 Targretin capsules 51 Cimzia ® certolizumab pegol 51 Infractions Appeal 51 ENDEAVOR IV 51 BRILINTA 51 oral ridaforolimus 51 ICANN Governmental 51 MoxDuo IR 51 SPIRIVA HandiHaler 51 Combidex 51 J Clin Oncol 51 Tavocept 51 motavizumab 51 Inc. Nasdaq CVTX 51 Adventrx 51 Sponsoring Organizations COSO 51 FASLODEX 51 ISTODAX 51 azficel T 51 ASH Annual Meeting 51 sorafenib tablets 51 NASDAQ CYTK announced 51 Doribax 51 MAGE A3 ASCI 51 sunitinib Sutent 51 LUX Lung 51 Alemtuzumab 51 trastuzumab DM1 T DM1 51 Xyrem ® 51 ofatumumab HuMax CD# 51 Arimidex anastrozole 51 pomalidomide 51 Somatuline Depot 51 Torisel 51 SEROQUEL XR 51 Inc. Nasdaq SEPR 51 Endocrine Society #st 51 Cloretazine ® 51 desvenlafaxine 51 eprodisate Fibrillex TM 51 Sanofi Acomplia 51 AA Amyloidosis 51 Medicines Adverse Reactions 51 Inc. Nasdaq VRUS 51 granted Ortec 51 Calcium Acetate 51 Phase III Clinical Trials 51 Inc. Nasdaq OPTR 51 Phase Ib II 51 Vertex telaprevir 51 Inc. Nasdaq AVRX 51 evaluating tivozanib 51 deforolimus 51 Arthritis Drugs 51 Inc. NASDAQ NTMD 51 Medical Oncology ESMO 51 PRIALT 51 Pixuvri 51 satraplatin Phase 51 sNDA 51 adalimumab Humira 51 Nasdaq ICOS 51 Genitourinary Cancers Symposium 51 Tocosol Paclitaxel 51 Adalimumab 51 See CLINICAL PHARMACOLOGY 51 Plenaxis TM 51 Expanded Indication 51 PLAVIX ® 51 Archexin 51 Iloperidone 51 Nasdaq BDSI 51 Rasilez HCT 51 methylnaltrexone 51 NSABP 51 PRNewswire FirstCall Amylin Pharmaceuticals 51 T DM1 51 Premarket Approval Application 51 ORENCIA R 51 BCCI Disciplinary 51 dopamine receptor agonist 51 severe gastroparesis 51 Submits NDA 51 IPC Governing 51 Quinamed 51 anthracyclines taxanes 51 Sebivo 51 Dyloject TM 51 Androxal TM 51 HER2 positive metastatic breast 51 AZILECT R 51 ASBMR 51 PANVAC VF 51 interferon gamma 1b 51 REBETOL combination therapy 51 Triolex 51 Submits Response 51 refractory chronic lymphocytic 51 orphan designation 51 Breast Surgeons 51 trabectedin 51 phase IIb trial 51 Xelox 51 Raptiva ® 51 Dispute Settlement Body 51 Product Characteristics 51 CALGB 51 T Pred 51 FOLOTYN ® 51 liprotamase 51 paliperidone palmitate 51 Teysuno 51 Prostate AdenoCarcinoma Treatment 51 Kuvan sapropterin dihydrochloride 51 Ziopharm 51 NASDAQ INGN 51 Trexima 51 Psoriasis Drug 51 Glybera R 51 INSPIRE Trial Phase III 51 novel trazodone formulation 51 Actemra 51 Inc. Nasdaq AMLN 51 Earlier Muthanna Harith 51 Receives Positive Opinion 51 Oncology Drug 51 ENESTnd 51 Vorapaxar 51 pralatrexate 50 Positive Opinion 50 FRDA 50 Aveed 50 Augment ™ Bone Graft 50 assessing T DM1 50 alogliptin 50 Pharmacoeconomics 50 Centralized Procedure 50 Hematology Annual Meeting 50 Premarket Approval PMA 50 Phase #b/#a clinical 50 alvespimycin 50 Advagraf 50 anidulafungin 50 Clinical Oncology ASCO Annual 50 Phenoptin 50 Horizant 50 Jevtana 50 Known hypersensitivity 50 Completes Patient Enrollment 50 Chemophase 50 Recurrent Chest Wall 50 Annual ICAAC 50 Cethromycin 50 romiplostim 50 prodrug stimulant 50 Annual Shareowner 50 TIMI Study Group 50 PSN# [002] 50 GARDASIL ® 50 Novartis Zometa 50 enzastaurin 50 PNT# 50 Clevudine 50 Reminyl galantamine 50 NASDAQ Listings Qualifications 50 Glybera 50 HyQ 50 ONGLYZA TM 50 Poster Presentation 50 HCV Protease Inhibitor 50 TRISENOX 50 Zenvia ™ 50 methylnaltrexone bromide 50 INCB# [001] 50 ganetespib 50 GSK# [001] 50 Hematologic 50 Corlux 50 Theratope 50 GW# [003] 50 Fabry Disease 50 ACIP 50 TWYNSTA ® 50 LY# [003] 50 Silodosin 50 orBec 50 efficacy endpoint 50 EORTC 50 Focetria 50 Zensana 50 Dr. Pingpank 50 Inc. Nasdaq BIOD 50 Yondelis 50 Vasovist 50 Victoza liraglutide 50 Orencia abatacept 50 chromium supplementation 50 Qutenza TM 50 Iressa gefitinib 50 framers Bahaa al Araji 50 Zoning Neighborhoods 50 BLA submission 50 Approvable Letter 50 USpella 50 Menaflex implant 50 GPhA 50 Satraplatin 50 Mirapexin 50 Br J Cancer 50 OMAPRO ™ 50 Oral Calcitonin 50 supplemental biologics 50 SWOG 50 AACR symposium 50 Neupro R 50 Hodgkin lymphoma HL 50 Erbitux cetuximab 50 ILLUMINATE 50 ACIP recommendations 50 OHRP 50 CAELYX 50 Tweeddale Area 50 Insmed Incorporated NASDAQ INSM 50 Marketing Authorization Applications 50 Research CDER 50 Emezine 50 PEG SN# 50 uncharted waters Potter 50 Rheumatology ACR Annual 50 Ticagrelor 50 pharmacokinetic PK study 50 telavancin 50 Tracleer ® bosentan 50 approvable letter 50 Hexvix 50 Velaglucerase Alfa 50 Supplemental Biologics License Application 50 Genasense ® 50 PARGLUVA 50 Yondelis ® 50 Clinical Oncology ASCO 50 Therapeutics TCT scientific 50 Trovax 50 Revlimid lenalidomide 50 Stockholders Meeting 50 AACR IASLC Joint 50 Securities Regulators CESR 50 Market Authorization Application 50 EORTC NCI 50 romidepsin 50 Prostate Cancer Symposium 50 BIO InvestorForum 50 oral cladribine 50 Amigal 50 Alogliptin 50 REYATAZ R 50 Hypertension ESH 50 Faslodex 50 forodesine 50 Molecular Origins 50 sipuleucel T 50 Nasdaq VRTX 50 GTCbio 50 POTA Review 50 tanespimycin 50 Phase #/#a trial 50 Phase III Trial 50 Preos 50 5 HT6 receptor 50 CPMP 50 Medicines CSM 50 phase Ib 50 QLT# 50 Bicifadine 50 oral FTY# 50 Swissmedic 50 Nasdaq BSTE 50 PRNewswire FirstCall ViroPharma Incorporated 50 motesanib 50 fingolimod 50 McNeil Pediatrics 50 Natalizumab 50 Hearings Panel 50 CYP#A# substrate 50 YERVOY 50 Ceflatonin 50 Golimumab 50 Nephrology Renal Week 50 Prospective Randomized 50 Hycamtin 50 PACE Monitoring 50 YONDELIS R 50 Increlex R 50 Related Biological 50 Roche Xeloda 50 #th Annual Interscience 50 Inc. Nasdaq ANDS 50 PROTECT II 50 Phase Ib study 50 NOXAFIL 50 Oracea TM 50 YONDELIS 50 Emezine R 50 azilsartan medoxomil 50 HCV SPRINT 50 panitumumab Vectibix 50 Eurand NV EURX 50 darbepoetin alfa Aranesp 50 Lilly Cymbalta 50 ECOFIN Council 50 Genetic Engineering Approval 50 NDA Submission 50 Fondaparinux 50 Uloric 50 NCCN guidelines 50 Arzerra TM 50 Cardiology ESC 50 Thyrogen 50 Multiple Sclerosis ECTRIMS 50 Lafourche Mayors 50 Clofarabine 50 REG2 50 seliciclib CYC# 50 NASDAQ SLXP 50 Fibrillex TM 50 Zingo TM 50 CIP TRAMADOL ER 50 Inc. NASDAQ AXYX 50 post operative ileus 50 LSE SHP NASDAQ SHPGY 50 Amylin AMLN 50 iloprost Inhalation Solution 50 Randomized Phase II 50 Juergen Engel Ph.D. 50 dasatinib 50 Phase III Trials 50 Continence Society 50 Immunization Practices recommends 50 Everolimus 50 R sipuleucel T 50 GlaxoSmithKline Plc diabetes 50 diabetic neuropathic pain 50 IV acetaminophen 50 OLEPTRO 50 Stavzor 50 carbamazepine phenobarbital phenytoin rifampin 49 investigational immunotherapy 49 mRCC 49 THALOMID 49 PrevOnco 49 Icatibant 49 Flutiform ™ 49 IMGN# 49 Nasdaq VPHM 49 PhosLo 49 Standardization CEN 49 casopitant 49 febuxostat 49 BENLYSTA 49 Tracleer R 49 IMiDs R 49 Natroba 49 Exalgo 49 Nasdaq SPPI 49 PREOS 49 Clolar ® 49 Vidaza azacitidine 49 OMAPRO 49 R sorafenib tablets 49 Bayer Nexavar 49 lintuzumab 49 rilonacept 49 Contrave NDA 49 Relistor 49 rALLy clinical trial 49 Cellular Tissue 49 Polymeropoulos 49 Inhaled Insulin 49 Safinamide 49 ICON7 49 Cerezyme Fabrazyme Myozyme Aldurazyme 49 Zybrestat 49 TRO# 49 Teriparatide 49 Injectafer 49 LibiGel Phase III 49 Announces Tentative Approval 49 Tolvaptan 49 FUSILEV ® 49 Ceflatonin ® 49 Vimpat R 49 Azacitidine 49 ponatinib 49 application sNDA 49 multicenter Phase 49 Gastrointestinal Cancers Symposium 49 ICA # 49 ruxolitinib 49 mapatumumab 49 histamine dihydrochloride 49 Photocure 49 Fludara ® 49 Lambert Eaton Myasthenic 49 Antibody Therapeutics 49 ISPOR 49 Mylotarg 49 FACTIVE tablets 49 Oracea ® 49 neratinib 49 PRISTIQ 49 Exforge HCT 49 Tysabri natalizumab 49 evaluating REVLIMID 49 Gamunex C 49 trastuzumab DM1 49 Surfaxin lucinactant 49 Pluristem Therapeutics 49 Long Term Efficacy 49 HuMax EGFr 49 single injection viscosupplement 49 PROactive Study 49 randomized Phase 2b 49 ASCRS 49 Sudhir Agrawal D.Phil 49 Hematide ™ peginesatide 49 COMFORT II 49 Adenuric R 49 Liraglutide 49 PRNewswire FirstCall Pharmos 49 angiogenesis inhibitor 49 Phase IIIb study 49 Faropenem 49 LymphoStat B TM 49 Citizen Petition 49 R roscovitine 49 PegIntron 49 Replagal 49 Aloxi Injection 49 DEXILANT 49 Fibrillex 49 Onsolis 49 Oglemilast 49 clazosentan 49 Announces Poster Presentations 49 Orphan Medicinal Product 49 NASDAQ ARRY 49 Liver EASL 49 trastuzumab emtansine T DM1 49 Neuvenge 49 AACR #nd Annual Meeting 49 Orexigen Therapeutics Inc 49 Ministerial Monitoring 49 Randomized Phase 49 Hana Biosciences 49 lumiliximab 49 Scientific Advice 49 Second Pivotal Phase 49 Trobalt 49 PRNewswire FirstCall Genaera 49 Special Shareholder Meeting 49 midstage studies 49 thetreatment 49 #st Annual Meeting 49 investigational compound 49 Trans Fat Task Force 49 aripiprazole Abilify 49 Herceptin trastuzumab 49 Cinryze ™ 49 entecavir 49 NCCTG N# 49 vidofludimus 49 mifamurtide 49 Recombinant DNA 49 Doxil ® 49 Subpart E 49 fidaxomicin 49 Patient Recruitment 49 metastatic castration resistant 49 Selective Cardiac Myosin 49 Riluzole 49 RANK Ligand inhibitor 49 exenatide Byetta 49 CLL8 49 journal Antimicrobial Agents 49 Testosterone MDTS ® 49 Praecis 49 Drug Applications INDs 49 EMPOWER ™ 49 ASCO Annual Meeting 49 CDISC Interchange 49 ASGT 49 TG MV 49 BARACLUDE R 49 naproxen esomeprazole magnesium 49 EXPAREL ™ 49 UPLYSO 49 Simulect 49 depsipeptide 49 randomized discontinuation trial 49 Wyeth Progenics 49 HuMax CD4 49 Cimzia certolizumab pegol 49 albinterferon alfa 2b 49 WILEX 49 OSI Tarceva 49 NSABP C 49 Vivus Qnexa 49 Bepreve 49 Neurodex